Oncology Xagena
Bone metastases are common in patients with non-small cell lung cancer ( NSCLC ), often causing pain and a decrease in quality of life ( QoL ). The effect of bone-targeted agents is evaluated by reduc ...
Results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy based on prospective measurement of PD-L1 expression in p ...
The purpose of GORTEC 2000-01 was to compare the long-term efficacy and safety of induction chemotherapy with Cisplatin ( P ) and 5-Fluorouracil ( F ) with or without Docetaxel ( T ) for larynx preser ...
Researchers conducted a phase IIb randomized trial of preoperative chemotherapy ( CT ) plus Trastuzumab ( T ), Lapatinib ( L ), or the combination of Trastuzumab plus Lapatinib in HER2+ operable breas ...
In the large pivotal phase II study, BIRCH, the investigational cancer immunotherapy Atezolizumab ( MPDL3280A; anti-PD-L1 ) met its primary endpoint and shrank tumors ( objective response rate; ORR ) ...
Longer term ( 18 month ) survival data from CheckMate -057, an open-label, randomized phase 3 study evaluating Nivolumab [ Opdivo ] ( n=292 ) versus Docetaxel [ Taxotere ] ( n=290 ) in previously trea ...
In 2020 the percentage of patients with a diagnosis of cancer in people with more than 65 years will exceed 70% and 28% in ethnic minorities. The treatment of cancer in these populations is challengin ...
Results from CheckMate -025, a phase 3 study comparing Nivolumab ( Opdivo ) to Everolimus ( Afinitor ) in advanced renal cell carcinoma ( RCC ) after prior anti-angiogenic treatment, showed a signific ...
Positive results from two phase II studies that evaluated the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with advanced non-small cell lung cancer ( NSCLC ) we ...
Early results from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with locally advanced or metastatic urothelial car ...
New data from KEYNOTE-001, a phase 1b study evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in naïve and previously-treated patients with advanced non-small cell lung cancer ( NSCLC ) wer ...
A Committee of the American Society of Clinical Oncology NSCLC Expert Panel carried out a systematic review of randomized controlled trials from January 2007 to February 2014 to provide evidence-base ...
Although activating mutations in the epidermal growth factor receptor ( EGFR ) gene are predictive markers for response to EGFR inhibitors, 30-40% of EGFR-mutant non-small cell lung cancer ( NSCLC ) p ...
T-DM1 ( Trastuzumab emtansine; Kadcyla ) treatment resulted in non-inferior, but not-superior, progression-free survival ( PFS ) compared with Trastuzumab plus a taxane ( HT ) in patients with locally ...
Results from two pivotal studies ( NP28673 and NP28761 ) have showen Alectinib, an oral investigational anaplastic lymphoma kinase inhibitor ( ALKi ), shrank tumours ( overall response rate; ORR: 50% ...
